Gemcitabine resistance in pancreatic ductal adenocarcinoma

Drug Resistance Updates

Volumn 23, Issue , 2015, Pages 55-68

  Binenbaum, Yoav ^a   Na'Ara, Shorook ^a,b   Gil, Ziv ^a,b,c  

^a Clinical Research Institute at Rambam   (Israel)

^b Department of Otolaryngology Head and Neck Surgery ^*  (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Chemoresistance; Environment mediated drug resistance; Gemcitabine; Metabolism; Pancreatic ductal adenocarcinoma

Indexed keywords

DRUG METABOLITE; GEMCITABINE; MICRORNA; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; ENZYME INHIBITOR; RIBONUCLEOTIDE REDUCTASE; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER SCREENING; DNA DAMAGE; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; ENZYME REGULATION; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; RIBONUCLEOTIDE REDUCTASES; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84947420404     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2015.10.002     Document Type: Article

References (119)

1. J.L. Abbruzzese, R. Grunewald, E.A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, M.N. Raber, and et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J. Clin. Oncol. 9 3 1991 491 498
2. H. Achiwa, and et al. Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer Cancer Sci. 95 2004 753 757
3. M. Akada, T. Crnogorac-Jurcevic, S. Lattimore, P. Mahon, R. Lopes, M. Sunamura, S. Matsuno, and N.R. Lemoine Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer Clin. Cancer Res. 11 8 2005 3094 3101 10.1158/1078-0432.CCR-04-1785
4. H. Akita, and et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma Oncogene 28 2009 2903 2909
5. S. Ali, and et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF Cancer Res. 70 2010 3606 3617
6. A. Arlt, and et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death Oncogene 22 2003 3243 3251
7. N.B. Arnold, N. Arkus, J. Gunn, and M. Korc The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer Clin. Cancer Res. 13 2007 18 26
8. S. Arora, and et al. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4 J. Biol. Chem. 288 2013 21197 21207
9. S. Bafna, S. Kaur, N. Momi, and S.K. Batra Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin Br. J. Cancer 101 2009 1155 1161
10. M. Bahra, and et al. Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas Pancreas 41 2012
11. G. Bepler, and et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer J. Clin. Oncol. 24 2006 4731 4737
12. H.A. Burris, and et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 1997 2403 2413
13. S. Calabretta, and et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells Oncogene 2015 10.1038/onc.2015.270
14. Cancer: Principles and Practice of Oncology, 5th Edition by DeVita, Vincent T., Jr.; Hellman, Samuel; Rosenberg, Steven A.: Lippincott-Raven, Philadelphia, PA, U.S.A. 9780397515738 Hardcover, Fifth Edition - Tin Can Mailman, Arcata. (n.d.). Retrieved November 29, 2014, from http://www.abebooks.com/Cancer-Principles-Practice-Oncology-5th-Edition/126561158/bd
15. P. Ceppi, and et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine Ann. Oncol. 17 2006 1818 1825
16. Y.-W. Chen, and et al. Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells Mol. Biosyst. 7 2011 3065 3074
17. G.C. Chu, A.C. Kimmelman, A.F. Hezel, and R.A. DePinho Stromal biology of pancreatic cancer J. Cell Biochem. 101 2007 887 907
18. S.G. Chun, W. Zhou, and N.S. Yee Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer Cancer Biol. Ther. 8 2009 1328 1339
19. J. Ciccolini, C. Mercier, L. Dahan, and N. André Integrating pharmacogenetics into gemcitabine dosing - time for a change? Nat. Rev. Clin. Oncol. 8 2011 439 444
20. S. Dangi-Garimella, and et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2 Cancer Res. 71 2011 1019 1028
21. R. de las Peñas, and et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients Ann. Oncol. 17 2006 668 675
22. D. Delitto, and et al. Abstract 5028: CXCL10 within the tumor microenvironment induces gemcitabine resistance in pancreatic cancer cells Cancer Res. 75 2015 5028
23. C.E. Denlinger, B.K. Rundall, M.D. Keller, and D.R. Jones Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis Ann. Thorac. Surg. 78 2004 1207 1214 (discussion 1207-14)
24. M. Donadelli, and et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine Biochim. Biophys. Acta 1773 2007 1095 1106
25. A. Drakaki, and D. Iliopoulos MicroRNA-gene signaling pathways in pancreatic cancer Biomed. J. 36 2013 200 208
26. C. Dumontet, and et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 Br. J. Haematol. 106 1999 78 85
27. M.S. Duxbury, H. Ito, M.J. Zinner, S.W. Ashley, and E.E. Whang Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells Clin. Cancer Res. 10 7 2004 2307 2318
28. N. Funamizu, and et al. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase? 2010 471 475 10.3892/or
29. C.M. Galmarini, and et al. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine Int. J. Cancer 97 2002 439 445
30. C.M. Galmarini, M.L. Clarke, L. Jordheim, C.L. Santos, E. Cros, J.R. Mackey, and C. Dumontet Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene BMC Pharmacol. 4 1 2004 8 10.1186/1471-2210-4-8
31. V. Gandhi, J. Legha, F. Chen, L.W. Hertel, and W. Plunkett Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA Cancer Res. 56 1996 4453 4459
32. L.a. Garraway, and P.a. Jänne Circumventing cancer drug resistance in the era of personalized medicine Cancer Discovery 2 2012 214 226
33. I. Garrido-Laguna, and et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer Clin. Cancer Res. 17 2011 5793 5800
34. Y. Ge, T.L. Jensen, M.L. Stout, R.M. Flatley, P.J. Grohar, Y. Ravindranath, L.H. Matherly, and J.W. Taub The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines Cancer Res. 64 2 2004 728 735
35. E. Giovannetti, and et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res. 66 2006 3928 3935
36. E. Giovannetti, and et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity Cancer Res. 70 2010 4528 4538
37. V. Giroux, J. Iovanna, and J.-C. Dagorn Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance FASEB J. 20 2006 1982 1991
38. Y.G. Goan, B. Zhou, E. Hu, S. Mi, and Y. Yen Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line Cancer Res. 59 17 1999 4204 4207
39. J. Guillermet-Guibert, and et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug Mol. Cancer Ther. 8 2009 809 820
40. X. Guo, and et al. Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines Cancer Lett. 290 2010 104 113
41. A. Habiro, and et al. Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells Biochem. Biophys. Res. Commun. 316 2004 71 77
42. S. Hamada, A. Masamune, S. Miura, K. Satoh, and T. Shimosegawa MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX Cell Signal. 26 2013 179 185
43. V.W.T.R. Van Haperen, and et al. Development and Molecular Characterization of a 2′,2′-difluorodeoxycytidine-resistant Variant of the Human Ovarian Carcinoma Cell Line A2780 1994 4138 4143
44. V. Heinemann, L.W. Hertel, G.B. Grindey, and W. Plunkett Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine Cancer Res. 48 1988 4024 4031
45. V. Heinemann, and et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation Cancer Res. 52 1992 533 539
46. H. Hernández-Vargas, and et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance Breast Cancer Res. Treat. 102 2007 157 172
47. A.F. Hezel, A.C. Kimmelman, B.Z. Stanger, N. Bardeesy, and R.a. Depinho Genetics and biology of pancreatic ductal adenocarcinoma Genes Dev. 20 2006 1218 1249
48. M. Hidalgo Pancreatic cancer N. Engl. J. Med. 362 2010 1605 1617
49. C.-C. Ho, and et al. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy Lung Cancer 59 2008 105 110
50. A. Horii, Y. Saiki, T. Nakano, C. Kudo, and M. Sunamura Abstract 5473: human cancer cells acquire chemoresistance to gemcitabine mainly through loss-of-function mutations in the DCK gene Cancer Res. 75 2015 5473
51. R.H. Hruban, and N. Fukushima Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs Mod. Pathol. 20 Suppl. 1 2007 S61 S70
52. S.W. Hung, and et al. Defective hCNT1 transport contributes to gemcitabine defects using a nanoparticle approach Cancer Lett. 359 2015 1 8
53. H. Ijichi, A. Chytil, A.E. Gorska, M.E. Aakre, B. Bierie, M. Tada, D. Mohri, K. Miyabayashi, Y. Asaoka, S. Maeda, T. Ikenoue, K. Tateishi, C.V. Wright, K. Koike, M. Omata, and H.L. Moses Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma J. Clin. Invest. 121 10 2011 4106 4117 10.1172/JCI42754
54. Infinity Reports Update from Phase 2 Study of Saridegib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer. News Release - Infinity Pharmaceuticals, Inc. (n.d.). Retrieved January 3, 2015, from (http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID=1653550&highlight=).
55. M.A. Jacobetz, and et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer 2013 112 120 10.1136/gutjnl-2012-302529
56. A. Jimeno, and et al. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer Mol. Cancer Ther. 9 2010 311 318
57. L.E. Jones, M.J. Humphreys, F. Campbell, J.P. Neoptolemos, and M.T. Boyd Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival Clin. Cancer Res. 10 2004 2832 2845
58. L.P. Jordheim, E. Cros, M.H. Gouy, C.M. Galmarini, S. Peyrottes, J. Mackey, C. Perigaud, and C. Dumontet Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug Clin. Cancer Res. 10 16 2004 5614 5621 10.1158/1078-0432.CCR-04-0506
59. L.P. Jordheim, O. Guittet, M. Lepoivre, C.M. Galmarini, and C. Dumontet Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells Mol. Cancer Ther. 4 2005 1268 1276
60. L.P. Jordheim, C.M. Galmarini, and C. Dumontet Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells Cancer Chemother. Pharmacol. 58 2006 547 554
61. H.-Q. Ju, and et al. Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation Mol. Cancer Ther. 14 2015 788 798
62. C.P. Jung, M.V. Motwani, and G.K. Schwartz Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit Clin. Cancer Res. 7 8 2001 2527 2536
63. H. Kazuno, K. Sakamoto, A. Fujioka, M. Fukushima, A. Matsuda, and T. Sasaki Possible antitumor activity of 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line Cancer Sci. 96 5 2005 295 302 10.1111/j.1349-7006.2005.00046.x
64. J.A. Kelber, T. Reno, S. Kaushal, C. Metildi, T. Wright, K. Stoletov, J.M. Weems, F.D. Park, E. Mose, Y. Wang, R.M. Hoffman, A.M. Lowy, M. Bouvet, and R.L. Klemke KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer Cancer Res. 72 10 2012 2554 2564 10.1158/0008-5472.CAN-11-3552
65. M.P. Kim, and G.E. Gallick Gemcitabine resistance in pancreatic cancer: picking the key players Clin. Cancer Res. 14 2008 1284 1285
66. S.I. Kozinn, and et al. MicroRNA profile to predict gemcitabine resistance in bladder carcinoma cell lines Genes Cancer 4 2013 61 69
67. J.R. Kroep, and et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines Br. J. Cancer 83 2000 1069 1076
68. J.R. Kroep, and et al. Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity 1 Supported by Eli Lilly & Co, International and The Netherlands. Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity 1. 2002
69. Y. Kuramitsu, K. Taba, S. Ryozawa, K. Yoshida, X. Zhang, T. Tanaka, S. Maehara, Y. Maehara, I. Sakaida, and K. Nakamura Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry Anticancer Res. 30 9 2010 3367 3372
70. P. Lecca Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms Drug Discovery Today 00 2013
71. J.J. Lee, and et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression Proc. Natl. Acad. Sci. U.S.A. 111 2014 E3091 E3100
72. H. Li, and B.B. Yang Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2 Oncotarget 3 2012 1653 1668
73. H. Li, and B.B. Yang Friend or foe: the role of microRNA in chemotherapy resistance Acta Pharmacol. Sin. 34 2013 870 879
74. Y. Li, and et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells Cancer Res. 69 2009 6704 6712
75. K. Liang, Y. Lu, X. Li, X. Zeng, R.I. Glazer, G.B. Mills, and Z. Fan Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine Mol. Pharmacol. 70 3 2006 1045 1052 10.1124/mol.106.023333
76. X. Lin, and S.B. Howell Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin Mol. Pharmacol. 56 2 1999 390 395
77. C. Liang, X.-J. Yu, X.-Z. Guo, M.-H. Sun, Z. Wang, Y. Song, Q.-X. Ni, H.-Y. Li, N. Mukaida, and Y.-Y. Li MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine Oncotarget 6 16 2015 14440 14455
78. R.V. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Domine, F. Cardenal, J.M. Sánchez, P.H. Gumerlock, M. Tarón, J.J. Sánchez, K.D. Danenberg, P.V. Danenberg, and R. Rosell Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin. Cancer Res. 8 7 2002 2286 2291
79. M. Määttä, Y. Soini, A. Liakka, and H. Autio-Harmainen Differential expression of matrix metalloproteinase (MMP)-2 MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis Clin. Cancer Res. 6 7 2000 2726 2734
80. J.R. Mackey, R.S. Mani, M. Selner, D. Mowles, J.D. Young, J.A. Belt, C.R. Crawford, and C.E. Cass Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res. 58 19 1998 4349 4357
81. J.R. Mackey, and et al. Functional Nucleoside Transporters Are Required for Gemcitabine Influx and Manifestation of Toxicity in Cancer Cell Lines1 1998 4349 4358
82. S.-I. Maehara, and et al. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells Int. J. Cancer 112 2004 184 189
83. K. Mann, and et al. Post-translational modifications of ribonucleotide reductase can explain acquired gemcitabine resistance in pancreatic cancer Pancreatology 15 2015 S20
84. R. Maréchal, and et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma Clin. Cancer Res. 15 2009 2913 2919
85. D.W. McMillin, J.M. Negri, and C.S. Mitsiades The role of tumour-stromal interactions in modifying drug response: challenges and opportunities Nat. Rev. Drug Discovery 12 2013 217 228
86. E. Mini, S. Nobili, B. Caciagli, I. Landini, and T. Mazzei Cellular pharmacology of gemcitabine Ann. Oncol. 17 Suppl. 5 2006 v7 v12
87. C.J. van Moorsel, H.M. Pinedo, G. Veerman, A.M. Bergman, C.M. Kuiper, J.B. Vermorken, W.J. van der Vijgh, and G.J. Peters Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines Br. J. Cancer 80 7 1999 981 990 10.1038/sj.bjc.6690452
88. S. Mori-Iwamoto, Y. Kuramitsu, S. Ryozawa, K. Taba, M. Fujimoto, K. Okita, K. Nakamura, and I. Sakaida A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines Mol. Med. Rep. 1 3 2008 429 434
89. G. Mu, L. Zhang, H. Li, Y. Liao, and H. Yu Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer Dig. Dis. Sci. 60 2015 1067 1080
90. S. Nakahira, and et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer Int. J. Cancer 120 2007 1355 1363
91. Y. Nakano, and et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells Br. J. Cancer 96 2007 457 463
92. T. Namba, R. Kodama, S. Moritomo, T. Hoshino, and T. Mizushima Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway Cell Death Dis. 6 2015 e1795
93. A. Neesse, and et al. Stromal biology and therapy in pancreatic cancer Gut 60 2011 861 868
94. S.S.W. Ng, M. Tsao, and S. Chow Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells inhibition of phosphatidylinositide 3-Kinase enhances gemcitabine-induced apoptosis in human pancreatic Cancer Cells 1. 2000 5451 5455
95. K.P. Olive, and et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
96. B.C. Özdemir, and et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival Cancer Cell 25 2014 719 734
97. J.-K. Park, E.J. Lee, C. Esau, and T.D. Schmittgen Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma Pancreas 38 2009 e190 e199
98. C. Poon, C. He, D. Liu, K. Lu, and W. Lin Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer J. Control Release 201 2015 90 99
99. P. Pourquier, C. Gioffre, G. Kohlhagen, Y. Urasaki, F. Goldwasser, L.W. Hertel, S. Yu, R.T. Pon, W.H. Gmeiner, and Y. Pommier Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I Clin. Cancer Res. 8 8 2002 2499 2504
100. A. Purushothaman, S.K. Babitz, and R.D. Sanderson Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma J. Biol. Chem. 287 2012 41288 41296
101. J. Rohloff, and et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma 2002 1270 1275 10.1038/sj/bjc/6600232
102. V.W. Ruiz van Haperen, and et al. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts Eur. J. Cancer 29A 1993 2132 2137
103. J. Schmidt, D. Ja, K. Hoffmann, and M.W. Bu Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring J. Immunother. (Hagerstown, Md.: 1997) 30 2007 108 115 10.1097/01.cji.0000211317.15278.27
104. C. Servais, and N. Erez From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation J. Pathol. 229 2013 198 207
105. R. Singh, and N. Saini Downregulation of BCL2 by miRNAs augments drug-induced apoptosis - a combined computational and experimental approach J. Cell Sci. 125 2012 1568 1578
106. S. Singh, S.K. Srivastava, a Bhardwaj, L.B. Owen, and a P. Singh CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy Br. J. Cancer 103 2010 1671 1679
107. G. Sliutz, J. Karlseder, C. Tempfer, L. Orel, G. Holzer, and M.M. Simon Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy Br. J. Cancer 74 2 1996 172 177
108. A. Stathis, and M.J. Moore advanced pancreatic carcinoma: current treatment and future challenges Nat. Rev. Clin. Oncol. 7 2010 163 172
109. S.P. Thayer, and et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis Nature 425 2003 851 856
110. Y. Tokunaga, and et al. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells Eur. J. Cancer 2015 1 10 10.1016/j.ejca.2015.05.013
111. V.W. van Haperen, G. Veerman, J.B. Vermorken, H.M. Pinedo, and G. Peters Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine Biochem. Pharmacol. 51 1996 911 918
112. Vegard Tjomsland, Lina Niklasson, Per Sandström, Kurt Borch, Henrik Druid, Charlotte Bratthäll, Davorka Messmer, Marie Larsson, and Anna Spångeus The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma Clin. Dev. Immunol. 2011 2011 10.1155/2011/212810 Article ID 212810, 12 pages
113. I. Vlodavsky, and Y. Friedmann Heparan sulfate proteoglycans molecular properties and involvement of heparanase in cancer metastasis and angiogenesis J. Clin. Invest. 108 3 2001 341 347 10.1172/JCI13662
114. Z. Wang, and et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway Cancer Res. 69 2009 2400 2407
115. N. Weizman, and et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase Oncogene 2013 1 8 10.1038/onc.2013.357
116. WHO Globocan Estimated Cancer Incidence and Mortality Worldwide in 2012 2012 At (http://globocan.iarc.fr/Pages/fact-sheets-population.aspx?country=900)
117. Y. Youyun, L. Hailan, L. Zhaomin, Z. Zijin, Y.-S. Michelle, C. Qipeng Fan, E. Max Schmidt, C. Gabriela, X. Jingwu, C. Liang, C. Jey-Hsin, and Z. Jian-Ting Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers Int. J. Biochem. Mol. Biol. 2 2011 89 98
118. H. Yoon, J.-K. Min, J.W. Lee, D.-G. Kim, and H.J. Hong Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2 Biochem. Biophys. Res. Commun. 405 2011 333 337
119. Y. Zhao, and et al. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer Target Oncol. 2015 10.1007/s11523-015-0360-2